DelveInsight's "CABLIVI Market Size, Forecast, and Market Insight Report" highlights the details around CABLIVI, a von ...

The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...

The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent.

The FDA approved a one-time, five-minute IV bolus infusion of tenecteplase for adults with acute ischemic stroke. Image: Adobe Stock "The approval of TNKase represents a meaningful advancement in ...

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

This is considerably faster than the standard of care, Activase (alteplase), which is administered as an intravenous bolus followed by a 60-minute infusion. Genentech, the manufacturer of TNKase ...

Developed by Sanofi, CABLIVI is the first FDA-approved nanobody therapy for this condition. Increasing awareness, improved diagnostic rates, and rising demand for targeted therapies in hematology ...

Patients were then randomized to receive an intravenous infusion of either 15 µg/kg salbutamol ... Conclusion: A single-dose intravenous salbutamol bolus of 15 µg/kg administered over 10 mins ...

The author is looking forward to seeing how Beam Therapeutics would do in their clinical trials of single-base DNA editing.

Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in acute ischaemic stroke (AIS). The drug, which has been authorised for use in ...

The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades. It offers a significant advantage over alteplase by enabling ...